Valuation check: VPHIF's profit margin is -60.18%, below the sector sector average of 13.4%.
Get informed when a big investor buys or sells
+ FollowAs of Jul 2024
Trailing 12 months ending Jul 2024
The latest profit margin for VPHIF is -60.18% as of July 2024. That compares with -53.52% in the prior-year period — down 12.4% year over year. That is below the sector sector average of 13.4%. Investors often review this figure alongside Valeo Pharma's historical trend and sector peers before judging valuation or financial health.
Over the past year, VPHIF's profit margin moved from -53.52% to -60.18% — a 12.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Valeo Pharma's valuation or profitability profile.
Against its sector companies, VPHIF currently prints -60.18% for profit margin, while the sector average sits near 13.4%. That is roughly 549.0% below the sector mean. Large gaps often invite a closer look at Valeo Pharma's growth, margins, and balance sheet.
Profit Margin shows how effectively Valeo Pharma converts resources into returns. At -60.18%, VPHIF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -53.52% in the prior-year period — down 12.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting VPHIF's profit margin (-60.18%), review year-over-year change from -53.52%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.